Machine learning approaches for customized docking scores: Modeling of inhibition of Mycobacterium tuberculosis enoyl acyl carrier protein reductase
暂无分享,去创建一个
Gary B. Fogel | Jonathan Tran | David Hecht | Stephen Johnson | G. Fogel | Jonathan Tran | David Hecht | Stephen Johnson
[1] R. Kroemer. Structure-based drug design: docking and scoring. , 2007, Current protein & peptide science.
[2] J. Musser,et al. Genotypic characterization of drug-resistant Mycobacterium tuberculosis isolates from Peru. , 1998, Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[3] Christopher R. Corbeil,et al. Towards the development of universal, fast and highly accurate docking/scoring methods: a long way to go , 2008, British journal of pharmacology.
[4] D. Hecht,et al. High-Throughput Ligand Screening via Preclustering and Evolved Neural Networks , 2007, IEEE/ACM Transactions on Computational Biology and Bioinformatics.
[5] W. Jacobs,et al. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. , 1994, Science.
[6] Robert Stroud,et al. Pyrrolidine carboxamides as a novel class of inhibitors of enoyl acyl carrier protein reductase from Mycobacterium tuberculosis. , 2006, Journal of medicinal chemistry.
[7] T. Halgren. Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94 , 1996, J. Comput. Chem..
[8] P Willett,et al. Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.
[9] P. Ortiz de Montellano,et al. Inhibition of the Mycobacterium tuberculosis enoyl acyl carrier protein reductase InhA by arylamides. , 2007, Bioorganic & medicinal chemistry.
[10] G. Besra,et al. Pathway to Synthesis and Processing of Mycolic Acids in Mycobacterium tuberculosis , 2005, Clinical Microbiology Reviews.
[11] Gary B. Fogel,et al. High-Throughput Ligand Screening via Preclustering and Evolved Neural Networks , 2007, IEEE ACM Trans. Comput. Biol. Bioinform..
[12] J. T. Crawford,et al. ethA, inhA, and katG Loci of Ethionamide-Resistant Clinical Mycobacterium tuberculosis Isolates , 2003, Antimicrobial Agents and Chemotherapy.
[13] René Thomsen,et al. MolDock: a new technique for high-accuracy molecular docking. , 2006, Journal of medicinal chemistry.
[14] Włodzisław Duch,et al. Artificial intelligence approaches for rational drug design and discovery. , 2007, Current pharmaceutical design.
[15] Jian Zhang,et al. Focused combinatorial library design based on structural diversity, druglikeness and binding affinity score. , 2005, Journal of combinatorial chemistry.
[16] Eric J Martin,et al. Target-biased scoring approaches and expert systems in structure-based virtual screening. , 2004, Current opinion in chemical biology.
[17] D. C. Sullivan,et al. Exploiting Structure—Activity Relationships in Docking. , 2008 .
[18] Shan Chang,et al. Complex-type-dependent scoring functions in protein-protein docking. , 2007, Biophysical chemistry.
[19] J. Bajorath,et al. Docking and scoring in virtual screening for drug discovery: methods and applications , 2004, Nature Reviews Drug Discovery.
[20] David H. Wolpert,et al. No free lunch theorems for optimization , 1997, IEEE Trans. Evol. Comput..
[21] Gary B. Fogel,et al. QSAR using evolved neural networks for the inhibition of mutant PfDHFR by pyrimethamine derivatives , 2008, Biosyst..
[22] N. Guex,et al. SWISS‐MODEL and the Swiss‐Pdb Viewer: An environment for comparative protein modeling , 1997, Electrophoresis.